Search

To celebrate International Clinical Trials Day, we want to highlight the importance of research and how relevant it is in Spain

Meet Mikrobiomik, our new member. We talk with Juan Basterra, CEO of the company

The results show the high efficacy and safety of PRS CK STORM as a medicine to prevent and treat the cytokine storm associated with infectious processes of any kind, including COVID-19. Longside

AseBio partners develop almost 200 products to improve the agrifood system and protect the planet in a context of great challenges. In 2021, Spanish biotechnology companies attracted 14% of the

Meet PVpharm, our new member. We talk with José Alberto Ayala Ortiz, CEO of the company

The results show the high efficacy and safety of PRS CK STORM as a medicine to prevent and treat the cytokine storm associated with infectious processes of any kind, including COVID-19. The company

Con esta operación, la biotecnológica gallega se convierte así en nuevo socio estratégico del grupo Maymó

Judit Anido joins Nuage Therapeutics as co-founder and CEO and becomes member of the Board of Directors

AseBio, in collaboration with Biocat, the Government of Catalonia and the Barcelona City Council, will be hosting one of the most important international biotechnology events in southern Europe at the

Oryzon Genomics, S.A., today reported financial results for the first quarter of 2022 and provided an update on recent developments

BCN HEALTH is organising the conference “Jornada de Acceso al Mercado de Medicamentos, Tratamientos de Coste Elevado y Medición de Resultados en Salud” on 18th May at the Hotel Hilton Barcelona

It’s been a week since AseBio’s event of the year, which brought together some 145 organisations and over 260 professionals. We spoke with Kaudal, our main sponsor, about their impressions and goals

The closing of the company’s B Series follows an oversubscribed $20m A round in 2020

Meet Celtarys Research, our new member. We talk with Sonia Martínez Arca, CEO of the company

De entre las distintas patologías, confiesan que se sienten menos cómodos al hablar de salud sexual, depresión e infertilidad

Oryzon Genomics, S.A, announced today the start of a preclinical collaboration on Kabuki Syndrome with researchers from Kennedy Krieger Institute and Johns Hopkins University

Dr Mark Bonyhadi is an experienced executive with over 30 years in the biopharmaceutical industry

Oryzon Genomics, S.A., announced today that its management will give an update on corporate progress at several international events in May